ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on Twitter

Kidney Week

Abstract: TH-PO173

Effects of Rituximab in Adult Patients with Minimal Change Disease

Session Information

Category: Glomerular

  • 1005 Clinical Glomerular Disorders


  • Roccatello, Dario, Ospedale San GIovanni Bosco, Torino, Italy
  • Sciascia, Savino, Ospedale San GIovanni Bosco, Torino, Italy
  • Fenoglio, Roberta, Ospedale San GIovanni Bosco, Torino, Italy

Minimal change disease (MCD) accounts for 15-20 % of adult nephrotic syndrome cases; adult-MCD patients (pts) may have more severe clinical features than pediatric pts. Therefore, active therapy and remission are very relevant for these patients. In children, rituximab (RTX) has been used since 2006 to treat frequently relapsing NS. In adults, data about the efficacy of RTX for MCD is limited. It is still not clear whether RTX is best used to induce remission or to maintain it, what the optimal dose should be and whether repeated doses improve response rates and prolong remission. We report a monocentric experience on the use of RTX in adult biopsy-proven MCD


Our series includes 5 adult pts (2 males and 3 females), aged 27-73 yrs treated with RTX (4 weekly doses of RTX 375 mg/m2 or 1 gr two weeks apart). RTX was administrated as a rescue therapy in 2 pts (1 pt with previous long term corticosteroid therapy; 1 pt received corticosteroids and immunosuppressive drugs in infancy). 3 pts with major risk factors precluding corticosteroids or conventional immunosuppression received RTX as a first-line treatment.


Proteinuria decreased from 8.4 (19.5-4.8) g/24 h to 0.03 g/24 h after 6 months; creatinine decreased from 1.44 (0.7-3.2) mg/dl to 0.86 (0.7-1.1) mg/l. 3 pts achieved a complete renal remission, in 1 pt proteinuria decreased by 50%. 1 pt didn’t achieved any response at 10 months; a ri-biopsy showed a focal-segmental-glomerulosclerosis. RTX successfully depleted CD19 lymphocytes in 100% of pts for at least 6 months. The follow-up ranged from 3 months to 24 months. No clinically relevant adverse events have been observed.


Our study shows a remarkable efficacy of RTX in treatment of MCD. RTX can be an attractive alternative as induction therapy or to manage recurrent forms of MCD. RTX may be preferentially used in pts at a high risk of development of the adverse effects of corticosteroids and should be considered as an important treatment alternative in patients with recurrent nephrotic syndrome. Randomized controleld trials are needed to confirmed our observations.